Citius Pharmaceuticals Posts First Revenue Amid Listing Risk

Citius Pharmaceuticals ( (CTXR) ) just unveiled an update.

On February 9, 2026, Citius Pharmaceuticals received notice that its Nasdaq-listed common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day grace period to regain compliance or face potential delisting, though trading under the CTXR symbol continues while the company evaluates remedies. Separately, on February 13, 2026, the company reported its first-ever revenue of $3.9 million from LYMPHIR sales following the drug’s December 2025 U.S. launch, alongside $20.9 million in equity financing, reduced R&D spending, and a narrower quarterly net loss, underscoring an early but pivotal commercial inflection amid ongoing Nasdaq listing risk and continued investment in its late-stage pipeline.

Citius Oncology’s LYMPHIR launch has seen early U.S. physician uptake via a nationwide distributor network, supported by an AI-enabled commercial platform targeting a concentrated prescriber base in this rare cancer market. Management is also pursuing international access through named patient programs in Europe and the Middle East and exploring broader clinical utility via investigator-initiated combination studies, moves that could expand LYMPHIR’s addressable market and reinforce Citius Oncology’s competitive position.

For the quarter ended December 31, 2025, Citius reported $7.7 million in cash and cash equivalents, with operations bolstered by capital raised at both the parent and oncology subsidiary levels. While general and administrative and stock-based compensation expenses increased, the company’s net loss narrowed year over year, reflecting the initial contribution from product revenue and tighter R&D spending as it engages with the FDA on next steps for Mino-Lok and Halo-Lido.

The most recent analyst rating on (CTXR) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Spark’s Take on CTXR Stock

According to Spark, TipRanks’ AI Analyst, CTXR is a Neutral.

The score is held down primarily by weak financial performance (no revenue, persistent losses, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). A meaningful offset is the positive corporate event (commercial launch of LYMPHIR), while valuation is not supportive due to negative earnings and no dividend.

To see Spark’s full report on CTXR stock, click here.

More about Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products, including catheter-salvaging therapy Mino-Lok and hemorrhoid treatment Halo-Lido. Through its 74.8%-owned subsidiary Citius Oncology, it markets LYMPHIR, a targeted immunotherapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma, in an underserved and growing oncology niche.

Average Trading Volume: 853,318

Technical Sentiment Signal: Strong Sell

Current Market Cap: $18.67M

See more insights into CTXR stock on TipRanks’ Stock Analysis page.